Last reviewed · How we verify
ETO
ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death.
ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death. Used for Small cell lung cancer, Testicular cancer, Lymphomas.
At a glance
| Generic name | ETO |
|---|---|
| Also known as | Etoposide |
| Sponsor | Italian Sarcoma Group |
| Drug class | Topoisomerase II inhibitor |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Etoposide binds to the topoisomerase II–DNA complex and stabilizes the cleavage complex, preventing the religation of DNA strands. This results in accumulation of DNA double-strand breaks, particularly during S and G2 phases of the cell cycle, triggering apoptosis in rapidly dividing cells. It is commonly used in combination chemotherapy regimens for various malignancies.
Approved indications
- Small cell lung cancer
- Testicular cancer
- Lymphomas
- Leukemias
- Sarcomas
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Secondary malignancy (acute leukemia)
- Hypersensitivity reactions
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding
- Decrease of Post-operative Complications by SCVO2 Monitoring an Optimisation of Cardiac Flow (NA)
- Deep Breathing With and Without Pressure Support and PEEP for Preoxygenation in Obese Patients (NA)
- Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- The Effect of Preoxygenation on Gastric Decompression in Laparoscopic Cholecystectomies (NA)
- PanACEA - STEP2C -01 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |